NH: Hello and thank you for tuning into the program. I’m your host Neil Howard here on Health Professional Radio....
Exclusive partner of Caris Molecular Intelligence in Australia and New Zealand. 
News
Findings from a new clinical appraisal of molecular profiling for clinical decision making in advanced cancer
A new publication written by an experienced group of Spanish oncologists and pathologists,1 has provided a clinical appraisal of molecular...
Guardant Health files lawsuit against Foundation Medicine
An original complaint against Foundation Medicine Inc. has recently been filed by Guardant Health Inc. Guardant seeks to recover damages and...
First results from the AURORA pilot study for molecular screening of patients with advanced breast cancer
In April 2014, OncoDNA, a clinical NGS provider affiliated with the Institute of Pathology and Genetics in Gosselies, Belgium, announced...
Measuring prevalence of oncogenic homologous recombination pathway mutations across 53,000 tumours
Results of a molecular profiling analysis to identify the frequency of Homologous Recombination Deficiencies (HRD) from approximately 53,000 tumours have...
Molecularly identifying candidates for the NCI-MATCH clinical trial
Caris Life Sciences® has announced a collaboration with the National Cancer Institute (NCI) for the NCI-Molecular Analysis for Therapy Choice...
Identifying patients with MSI-high (or mismatch repair deficient) solid tumours more likely to respond to immunotherapy
The primary objective of this study was to estimate the efficacy of the immunotherapy drug pembrolizumab in patients with MSI-High...
Tumour profiling reports optimised to molecularly identify genomic alterations for the TAPUR study
Caris is one of the first laboratories to have a test report optimised for ASCO’s Targeted Agent and Profiling Utilization...
Characterising total mutational load in multiple tumour types
The results of two molecular profiling studies provide detailed information on the characteristics of tumours with significant Total Mutational Load (TML)....
Caris update from ESMO 2016
Caris Life Sciences has recently passed the milestone of profiling over 100,000 solid tumours using a multiplatform approach. As part...
Caris Present New Outcomes Data from Over 4,700 Profiled Patients at ASCO 2016
At the recent ASCO annual meeting, Caris Life Sciences presented new and important outcomes data from over 4,700 patients that...
Caris presents at 2016 Society of Gynecologic Oncology
At the 2016 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer® recently held in San Diego, Caris Life...
- 1
- 2
Print 
PDFCreated: February 9, 2017 - Modified: August 18, 2017